TG Therapeutics Inc
TGTX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.37B
Close$
$0.44
99.3% downside
Current Fair Value
99.3% downsideOvervalued by 99.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $9.37 Billion |
|---|---|
| Enterprise Value | $9.65 Billion |
| Earnings per Share | $3.1 |
| Beta | 1.8 |
| Outstanding Shares | 141,770,283 |
Return
| Return on Equity | 73.08% |
|---|---|
| Return on Assets | 26.93% |
| Return on Invested Capital | 10.26% |
Valuation & Multiples
| P/E Ratio | 20.09 |
|---|---|
| PEG | -27.75 |
| Price to Sales | 12.33 |
| Price to Book Ratio | 15.41 |
| Enterprise Value to Revenue | 12.07 |
| Enterprise Value to EBIT | 68.6 |
| Enterprise Value to Net Income | 21 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 1.28 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 2, 2026
EPS Estimate
$0.37
Consensus analyst estimateRevenue Estimate
$245.47 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 61.30% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.02%▼ 76.42% |
|---|---|
| Total Invested | $237.89M▼ 96.15% |
| Investors Holding | 129▼ 336.00% |
About TG Therapeutics Inc
CEO: Michael Weiss
